A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)-MedSci.cn

A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Macaluso, FS; Ventimiglia, M; Fries, W; Viola, A; Cappello, M; Scrivo, B; Magnano, A; Pluchino, D; Camilleri, S; Garufi, S; Di Mitri, R; Mocciaro, F; Magri, G; Ferracane, C; Citrano, M; Graziano, F; Bertolami, C; Renna, S; Orlando, R; Rizzuto, G; Cottone, M; Orlando, A

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

科室

工具

服务